Enquiry/Quote
Nitroglycerin Controlled Release Tablets bulk supplier for pharma manufacturers

Nitroglycerin Controlled Release Tablets Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 2.6 mg, 6.5 mg, 9 mg

Reference Brands: Various Indian Brand Available

Category: Heart Disorder

Nitroglycerin Controlled Release Tablet is used to treat and prevent heart-related chest pain (angina). Angina occurs when the heart muscle is not getting enough blood. This medicine works by relaxing and widening blood vessels so blood can flow more easily to the heart. Nitroglycerin Controlled Release Tablets is available in Tablets and strengths such as 2.6 mg, 6.5 mg, 9 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Nitroglycerin Controlled Release Tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Nitroglycerin Controlled Release Tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description:

Nitroglycerin Controlled Release Tablets are a cardiovascular medication designed for the prevention of angina pectoris (chest pain) in patients with coronary artery disease. The active ingredient, nitroglycerin, is a nitrate that works by releasing nitric oxide in the body, which relaxes and dilates blood vessels. This vasodilation improves blood flow to the heart muscle and reduces the heart’s workload, helping prevent episodes of angina.

Unlike sublingual tablets, controlled-release tablets are formulated to provide a gradual and sustained release of nitroglycerin over 12–24 hours. This ensures steady blood levels of the drug, allowing prolonged protection against angina attacks and reducing the need for frequent dosing. The tablets are available in various strengths, typically 2.5 mg, 6.5 mg, 9 mg, and 12 mg.

Nitroglycerin Controlled Release Tablets are administered orally, usually once or twice daily, under the supervision of a healthcare professional. They are widely used in clinical settings for long-term management of angina and are available globally in both branded and generic formulations, manufactured under strict GMP standards.

Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Nitroglycerin Controlled Release Tablets are used for the prevention of angina pectoris (chest pain) in patients with coronary artery disease. Unlike sublingual tablets, controlled-release formulations provide a sustained release of nitroglycerin, helping to maintain steady blood levels and reduce the frequency of angina attacks over 12–24 hours.

These tablets contain nitroglycerin, a nitrate compound that releases nitric oxide in the body, causing vasodilation of blood vessels and reducing the heart’s workload. The controlled-release formulation ensures gradual absorption, providing prolonged therapeutic effects.

Common trade names include Minitran CR, Nitro-Dur CR, and Nitrolingual CR, along with multiple generic versions available worldwide.

Minitran CR is marketed by 3M, Nitro-Dur CR by Pfizer, and Nitrolingual CR by Novartis. Generic controlled-release tablets are produced by several pharmaceutical companies globally.

The generic name is nitroglycerin.

Brand names include Minitran CR, Nitro-Dur CR, Nitrolingual CR, and several regional generics.

It is manufactured in GMP-certified pharmaceutical facilities across the USA, Europe, India, and Latin America.

Yes, Nitroglycerin Controlled Release Tablets is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Nitroglycerin Controlled Release Tablets is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Trandolapril

Strength:
0.5 mg, 1 mg, 2 mg

Form: Tablets

Reference Brands: Mavik (USA), Gopten (EU)

View Details
Tirofiban Hydrochloride

Strength:
2.5 mg/mL

Form: Injection

Reference Brands: Aggrastat (USA)

View Details
Selexipag

Strength:
200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg

Form: Tablets / Injection

Reference Brands: Uptravi (USA/EU)

View Details
Edoxaban

Strength:
15 mg, 30 mg, 60 mg

Form: Tablets

Reference Brands: Savaysa (USA), Lixiana (EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.